Next generation CAR-T incorporating an inhibitory CAR (iCAR) for increased safety in solid tumors

Bassan D, et al. Poster presentation at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC). November 2022

ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D. as Chief Medical Officer

—Seasoned physician-scientist and R&D executive, with significant experience building and growing successful clinical development organizations— WEST HILLS, Calif., Sept. 13, 2022 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Jonathan Benjamin, M.D., Ph.D. as its chief medical officer. Dr. Benjamin will lead […]

ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development

—Senior healthcare executive with three decades’ global experience across large pharma and diverse start-up organizations in finance and business development— WEST HILLS, Calif., August 9, 2022 — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Vikram Lamba, M.B.M. […]

ImmPACT Bio Names Sylvain Roy as Chief Technology Officer

Longtime pharmaceutical industry executive brings over two decades of experience in cell and gene therapy, global technical operations, and leading high-performing teams — CAMARILLO, Calif., May 10, 2022 — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Sylvain Roy […]

ImmPACT Bio Names Venkat Yepuri as Chief Operating Officer

CAMARILLO, Calif., April 19, 2022 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Venkata (Venkat) P. Yepuri as chief operating officer. In this role, Mr. Yepuri will oversee business operations across the company. “Venkat is a senior operations leader with […]